ESR1 and breast carcinoma: To determine whether MST1/2 inhibition could inhibit the hormonal therapy-resistant ERα mutant in vivo, we generated ERα-Y537S-expressing MCF-7 xenografts as well as patient-derived xenograft (PDX) models bearing WHIM20 breast cancer cells.